Furthermore, the inhibition of oxidative phosphorylation has been shown to abrogate resistance to EGFR inhibitors in EGFR-driven lung cancers [176], docetaxel in prostate cancer [177], MAPK inhibitors in melanoma [178] and 5-fluorouracil (5FU) in colon cancers [179]. This evidence concerns the gene EGFR and lung cancer.